BioAtla Raises $45M For Antibody Therapeutics

San Diego- and Beijing-based BioAtla, a biotech startup focused on Conditionally Active Biologic (CAB) antibody therapeutics, announced over the weekend that it has raised $45M in funding. The funding came from the Global BIO Impact Fund (Global BIO). The funding is split between $15M in equity and an additional $30M in debt. BioAtla is led by Jay M. Short, Ph.D. BioAtla is focusing its research on cancer treatment. More information »